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Pharmacokinetics of recombinant human insulin-like growth
factor-i in dialysis patients
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Pharmacokinetics of recombinant human insulin-like growth factor-i
in dialysis patients. Six maintenance hemodialysis (MHD), six continous
ambulatory peritoneal dialysis (CAPD) and six normal adults underwent
pharmacokinetic studies of insulin-like growth factor-i (IGF-1). Each
subject received two separate subcutaneous injections of recombinant
human IGF-1 (rhlGF-1) (50 or 100 pg/kg) in random order separated by
7 to 21 days. Two different responses were observed. With the 50 jig/kg
dose, serum IGF-1 levels and the pharmacokinetic parameters were not
different between the three groups. With the 100 jig/kg dose, peak serum
IGF-1 concentrations were significantly greater in the MHD and CAPD
patients than in normals. However, by 12 to 14 hours after injection, serum
IGF-i was not different in the three groups. Although the Tm,,, area under
the curve and serum clearance of IGF-i were similar in the three groups,
the half-life and volume of distribution of rhIGF-1 was significantly
decreased in both MHD and CAPD patients. These data indicate that
IGF-1 pharmacokinetics are abnormal in maintenance dialysis patients.
Insulin-like growth factor-i (IGF-i) is a compound with broad
anabolic and antihyperglycemic actions that has a molecular
weight of 7650 kD [1, 2]. Synthesis of IGF-1, which occurs in
tissues throughout the body, is stimulated by growth hormone and
is suppressed by poor nutrition or severe catabolic stress. With the
development of recombinant DNA biosynthesis technology, re-
combinant human IGF-i (rhIGF-1) has been administered exper-
imentally to humans with a variety of clinical conditions as a
potential therapeutic agent [3]. Malnourished patients with
chronic renal failure have been given rhIGF-1 to improve their
protein balance [4]. Although the treatment of chronic renal
failure patients with rhIGF-1 will probably increase, there are
virtually no data on the serum concentrations or clearance rates of
IGF-1 in such patients during treatment. Because IGF-1 is present
in normal urine [51, the healthy kidney degrades many peptides [6]
and there appear to be abnormally high concentrations of serum
IGF binding proteins in renal failure [7, 8]. Hence, it is possible
that the pharmacokinetics of rhIGF-i are altered in renal failure.
We therefore carried out a pharmacokinetic study of the
response to two different doses of rhIGF-i in patients with
chronic renal failure. Patients undergoing either maintenance
1 Present address: Department of Nephrology, Hôpital Edouard Her-
riot and University Claude Bernard, Lyon, France.
Received for publication January 24, 1994
and in revised form October 17, 1994
Accepted for publication October 17, 1994
© 1995 by the International Society of Nephrology
hemodialysis (MHD) or continuous ambulatory peritoneal dialy-
sis (CAPD) were studied. Normal adults of similar age were
evaluated for comparison. The results of these studies indicate
that the pharmacokinetics of rhIGF-i are altered in renal failure.
Methods
Patients
Studies were carried out in six patients receiving MHD, six
patients undergoing CAPD and six normal adults. Exclusion
criteria included pregnancy, insulin and noninsulin dependent
diabetes mellitus, infection, vasculitis, autoimmune diseases, pres-
ence of malignancy, obesity or malnutrition (relative body weight
>120% or <80%), edema, proteinuria greater than 3 g per day,
alcoholism, other recreational drug use, and heart, lung or liver
failure. Subjects were not included if they received any catabolic
or cytotoxic medications during the preceding six months.
Characteristics of the patients are shown in Table 1. Except for
the serum urea and creatinine concentrations, there were no
differences between the three groups for any parameter in this
Table. Normal volunteers had a serum creatinine in the normal
range and no proteinuria on dipstick examination of the urine.
Patients received hemodialysis for 3.5 to 4.5 hours thrice weekly
with high-flux polysulfone membrane dialyzers and bicarbonate
containing dialysate. CAPD patients underwent four to five
exchanges daily with 1.5 to 2.0 liter of dialysate per exchange that
contained 1.5 to 425% dextrose and 7.0 mg'dl of calcium. MHD
patients had undergone hemodialysis for 46.6 17.6 (sEM)
months prior to the study. CAPD patients received peritoneal
dialysis for 12.8 4.0 months before the study. During the course
of this protocol, one hemodialysis patient transferred to CAPD
therapy because of problems with his vascular access. He was
restudied after four months of treatment with CAPD. This
protocol was approved by the Harbor-UCLA Medical Center
Human Subjects Committee. Informed written consent was ob-
tained from all subjects.
Protocol design
All subjects were admitted to the Clinical Research Center
(CRC) at Harbor-UCLA Medical Center on two occasions sepa-
rated by 7 to 21 days to receive either 50 or 100 jig/kg body weight
of rhIGF-1. Each individual received a different dose of rhIGF-1
on each CRC admission; the order of administration of the two
doses was determined randomly. MHD patients entered the CRC
immediately after a routine hemodialysis treatment and did not
receive another dialysis treatment until after the 24-hour blood
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Table 1. Characteristics of the subjects
Hemodialysis CAPD Normal
Age years 41.5 4.7 43.5 5.1 35.8 6.7
range, years 25—56 24—57 23—67
Sex ratio MIF 5/1 5/1 5/1
S. mgldl 10.9 1.la 13.9 1.6" 0.9 0.1
SUN mg/dl 50.3 6.6a 61.7 71b 13.2 0.9
Body weight kg 71.5 5•9a 71.5 8.2" 63.4 4.8
RBW % 96.6 6.9 95.4 5.1 93.5 4.8
BSA m2 1.85 0.06a 1.80 0.15" 1.68 0.08
Body fat % 22.3 2.3a 23.9 1.9" 21.3 2.5
Values are expressed as mean SEM. Abbreviations are: S,, serum
creatinine; SUN, serum urea nitrogen; RBW, relative body weight,
calculated from the NHANES data [9]; BSA, body surface area.
a Obtained about 13 to 18 hr after the end of the last hemodialysis
treatment
b Obtained after emptying the peritoneal cavity, the morning of the test
drawing two days later. The CAPD patients infused dialysate
containing 1.5% dextrose for the overnight dwell before the study.
They drained the dialysate at 7:00 a.m. the following morning and
did not reinfuse dialysate until after the 240 minute blood
drawing. All individuals were fasted from 10 p.m. the night that
they entered the CRC until after the 240 minute blood sample was
drawn at 12:00 p.m. the next day. Normal subjects only were
allowed to drink up to 500 ml of deionized water between 10:00
p.m. and 8:00 a.m. to compensate for urine losses.
At about 7:45 a.m., the morning after admission to the CRC, a
22-gauge butterfly needle was inserted into a peripheral arm vein
and kept there for the 24 hour period of the study. At approxi-
mately 8:00 a.m., subjects were given one subcutaneous injection
of rhIGF-1 in the right or left abdominal wall. Blood samples were
obtained at 10 and 5 minutes before the rhIGF-1 injection and at
the following times afterwards: 15, 30, 60 and 90 minutes and 2, 3,
4, 6, 8, 10, 12, 14 and 24 hours. Approximately 3 ml of whole blood
was collected in plain glass tubes and allowed to clot for 30
minutes at room temperature. After each blood drawing, the
needle and attached tubing were rinsed with heparinized saline.
Samples were centrifuged at 4°C, 2500 g for 15 minutes. The
supernatant serum was pipetted and immediately frozen at —20°C
in polyethylene tubes until measurement.
On the day of the rhIGF-1 injection, individuals received their
usual diet at 12:15 p.m. (a combined breakfast and lunch), 6:00
p.m. (supper) and 9:30 p.m. (snack). All subjects were then fasted
from 10:00 p.m. on that day until the final blood drawing at 8:00
a.m. the next morning. The CAPD patients usual four or five
peritoneal dialysis exchanges were commenced after the 12:00
p.m. blood drawing. However, the dwell times for the first three or
four exchanges were shortened; the overnight exchange was
always infused at 11:00 p.m. and was composed of 1.5% dextrose.
The dialysate was drained at 7:00 a.m. and not reinfused until
after 8:00 a.m. No patient received any medicine from 10:00 p.m.
on the first night until after the 240 minute blood drawing the next
day. The exception was a hypertensive MHD patient who received
nifedipine, 10 mg at 7:30 a.m., before the 50 pg/kg dose of
rhIGF-1.
After the 240 minute blood drawing, all individuals were given
their usual medications. No medicines were given from 9:30 p.m.
until after the final blood drawing the following morning. The
normal individuals received no medicines; during the CRC ad-
missions, the dialysis patients were given a multivitamin (Nephro-
vite®), ferrous sulfate, and often antihypertensive medicines.
Preparation of rhIGF-1
RhIGF-1 was obtained in vials containing 9.8 mg of pure dry
recombinant human IGF-1 and 0.3 mg of sulfoxide (a gift from
Ciba-Geigy Corp., courtesy of Dr. H.P. Guler), and stored at 4°C.
For preparation of the rhIGF-1 for administration, 0.98 ml
normal saline was slowly injected into the vial. The vial was then
gently rotated along its long axis, to avoid bubble formation, for
about 15 seconds. The rhIGF-1 solution was then rapidly trans-
ferred into an insulin syringe to be injected subcutaneously. The
maximum time between dilution and injection of rhIGF-1 did not
exceed 20 minutes.
Assays
Serum total IGF-1 concentration was measured in duplicate by
radioimmunoassay (RIA) after acid-ethanol extraction according
to Daughaday, Mariz and Blethen [10], except that the specimen
were centrifuged for 20 minutes at 4°C after acid-ethanol extrac-
tion. A polyclonal rabbit antibody from the NIH (courtesy of Dr.
Underwood) was used. Intra- and interassay variabilities were,
respectively, 7% and 14%. A comparison in our laboratory of the
methods of acid-ethanol extraction with the cryoprecipitation
technique [11] indicated that the two methods gave similar results,
although the acid-ethanol extraction technique yielded slightly
higher values (by 13.8%). Yves LeBouc, M.D. (Hôpital Armand-
Trousseau, Paris, France) remeasured IGF-1 in a number of
serum specimens from the normal subjects and hemodialysis
patients at four different time points using the acid chromatogra-
phy technique [12]. The results of the two sets of measurements
were quantitatively similar. There was also a good correlation
between the two sets of serum IGF-1 measurements (N = 39, r
0.72, P < 0.001).
Pharmacokinetic analyses
For the kinetic analyses, it was assumed that the injected dose
was completely absorbed. Cm is the observed maximal serum
concentration of IGF-1, and Tm is the time from injection until
the appearance of Cm for each individual subject. The serum
IGF-1 concentrations were fitted to a one-compartment open
model using a weighted, non-linear least-squares regression com-
puter analysis program (ADAPT; Drs. David D'Argenio and Alan
Schumitzky, Laboratory of Applied Pharmacokinetics, University
of Southern California) [13]. The pharmacokinetic parameters Ka
(absorption rate constant), Vd (apparent volume of distribution),
and Kel (elimination rate constant) were thus calculated. The
assay error pattern was linear, and weights were given to the data
points corresponding to the inverse variance of the assay weight-
ing. We examined a two-compartment model and found no
improvement in fit; therefore, we used the simpler one-compart-
ment model. In order to calculate the pharmacokinetic parame-
ters, the baseline value for IGF-1 was subtracted from each
measured serum IGF-1 concentration. To obtain the baseline
IGF-1 value, the two serum IGF-1 levels measured before the
rhIGF-1 injection were averaged. The serum IGF-1 half-life was
calculated by the formula:
Half-life = 0.693/Kel
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The area under the curve (AUC) for exogenous IGF-1 was
calculated from 0 to infinity by using the equation:
AUC = Dose/Kel Vd
Clearance of serum IGF-1 (SC!) after the subcutaneous injection
of rhIGF-1 was calculated as follows:
SC1 = Dose/AUC
The endogenous production rate of IGF-1 was estimated for each
patient in the three groups from the following equation:
P = Sd S
where P is the assumed endogenous IGF-1 production rate
(mg/day) as previously described [141. SC! is calculated from the
one-compartment model (see above) (liter/day), and S is the
baseline serum concentration of IGF-1 (tg/liter). This calculation
is based on the following assumptions: (1) Baseline IGF-1 levels
reflect the endogenous serum IGF-1 value for the entire 24 hour
period, as shown by Hizuka et al [15]. (2) There are no relatively
large, slowly exchanging compartments of IGF-1 in which both
synthesis and degradation are occurring. (3) P and SC1 do not
change after the load of rhIGF-1.
Statistical analysis
Values are given as the mean standard error of the mean
(sEM). A one-way analysis of variance (ANOVA), with adjustment
of P values for multiple comparisons, was performed to compare
the overall mean levels between groups. If the ANOVA indicated
a significant trend among groups, the Fisher exact test was used to
test for differences between individual groups. Similar statistical
analyses were used to compare the post-injection serum concen-
trations with the baseline values within each group. To determine
if there was a dose effect, a one-way analysis of variance with
repeated measures was performed to compare the results from
the two doses within the same group. Statistical significance was
taken as P < 0.05.
Results
The serum IGF-1 levels are shown in Figures 1 and 2 and Table
2. Figures 1 and 2 show the average values at a given time,
whereas Table 2 indicates the average maximum serum IGF-1
levels (Cm), which did not always occur at the same time.
Baseline serum IGF-1 concentrations were not different between
groups before the injection of either dose of rhIGF-1. After each
subcutaneous injection of rhIGF-1, there was a rapid and highly
significant rise in serum IGF-1 in each group of subjects. The Cm
and the increment in serum IGF-1 levels were significantly greater
with the 100 g rhIGF-1/kg dose as compared to the 50 g
rhIGF-1/kg dose for each group of subjects (P < 0.05; Table 2).
With the 50 tg/kg dose, serum IGF-1 increased by 386 54,
416 56 and 331 54 j.gfliter above baseline in the MHD,
CAPD and normal subjects, respectively. Among the three groups
of subjects given 50 g rhIGF-1/kg, there was no difference in
either the increment or in the absolute concentrations of serum
IGF-1 (Fig. 1, Table 2). Twenty-four hours after injection of
rhIGF-1, the serum IGF-1 remained significantly greater than
baseline only in the CAPD and normal subjects, by 61% and 43%,
respectively (P < 0.05 for each group).
0
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Fig. 1. Serum insulin-like growth factor-i (IGF-1) concentrations immedi-
ately before and after a subcutaneous injection of rhIGF-1, 50 ig/kg body
weight, in maintenance hemodialyis patients (A), CAPD patients (0), and
nor,nal individuals (•). Brackets indicate standard error of the mean. N =
6 for each group.
Time, minutes
Fig. 2. Serum IGF-i concentrations immediately before and after a subcu-
taneous injection of rhIGF-1, 100 pg/kg body weight, in maintenance
hemodialysis patients (A), CAPD patients (0), and normal individuals (•).
Brackets indicate SCM. N = 6 for each group. *Maintenance hemodialysis
patients vs. normal subjects, P < 0.05; tCAPD patients vs. normal
subjects, P < 0.05.
After the 100 pg/kg dose, the serum IGF-1 values increased
more in the dialysis patients than in the normal subjects (Fig. 2,
Table 2). Serum IGF-1 increased by a maximum of 810 73, 887
124 and 471 80 jLg/liter above baseline in the MHD, CAPD
and normal subjects, respectively (MHD vs. normal P < 0.05,
CAPD vs. normal P < 0.025). With 100 g rhIGF-1/kg, serum
IGF-1 was significantly greater in the MHD patients than in
normals at 90, 120, and 180 minutes. In CAPD patients, serum
IGF-1 was greater than in normal subjects at 120, 180 and 240
minutes after injection. Serum IGF-1 levels 24 hours after injec-
tion were almost identical in the three groups, and were 69%,
132% and 114% greater than baseline in the MHD, CAPD and
normal subjects, respectively (P < 0.05 for MHD, P < 0.025 for
CAPD and normals).
The Tm= did not differ with either the 50 g/kg or 100 pg/kg
dose among the three groups (Table 2). The half-life of rhIGF-1
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Table 2. Pharmacokinetic values for IGF-1 in the three groups of subjects
Dose
Hemodialysis CAPD Normal Hemodialysis CAPD Normal
rhlGF-1 50 pg/kg body wt rhIGF-1 100 pg/kg body wt
Baseline pg/liter
Cm,x pg/liter
pg/liter
156 14
543 63
386 54
148 33
564 87
416 56
180 24
496 81
331 54
205 25
1015 86a,d
810 73b,d
162 32
1049 156b,d
887 124c,d
166 22
637 85d
471 80'
Tmax hr 3.17 0.6 3.50 0.22 3.33 0.33 2.67 0.21 3.50 0.22 4.50 0.85
Half-life hr 5.3 1.7 5.7 1.8 10.4 3.4 6.0 1•7b 5•7 12b 12.8 2.2
AUC pgday/liter 172.2 36.9 245.1 48.2 199.2 28.1 381.7 100.9 443.5 84.l' 391.6 87.0
Vd liter/kg 0.09 0.02 0.07 0.01 0.15 0.04 0.10 0.O1C 0.08 0.01c 0.21 0.03
SCI mI/mm 16.6 2.3 13.5 3.6 12.7 2.5 17.0 3.5 12.6 1.7 14.3 2.9
Values are mean SEM. Six subjects were studied with both doses of rhIGF-1 in each group. Data presented are actual measurements except for
Half-life, AUC, VD, and SCI which are calculated using models (see Methods). Definitions are: Baseline, average of two serum IGF-1 values before
injection; Cmax, maximum serum IGF-1 concentration (within each group the Cm did not occur at the same time in all subjects); mx' difference
between maximum serum IGF-1 concentration and baseline; time of maximum serum IGF-1 concentration; AUC, area under curve for serum
IGF-1 after injection minus baseline level from 0 to cc (see text); Vd, volume of distribution; SCI, serum clearance of IGF-1, not adjusted for the fraction
absorbed.
Differs from normal: 'P < 0.05, hp < 0.025, P < 0.01
Differs from values obtained in the same group with the 50 pg/kg dose: d P < 0.05
Hemodialysis CAPD Normal
rhIGF-1; 50 pg/kg
PIUFI mg/day 3.64 0.48 2.51 0.73 3.18 0.64
IGF-1 mg/kg/day 52.6 8.5 32.8 6.2 49.9 8.4
rhIGF-1; 100 pg/kg
IGFi mg/day 4.75 0.90 2.66 0.48 3.08 0.47
1GF1 mg/kg/day 69.5 14.0 36.2 3.7 48.2 6.8
reduced by more than 50% in both the MHD and CAPD patients
as compared to normals (P < 0.005 for MHD or CAPD vs.
normal; Fig. 3).
The estimated endogenous production of IGF-1 (P) is shown in
Table 3. In general, the estimated P rates for the two doses of
rhIGF-1 within each group were similar. This was particularly true
for the CAPD patients and normal subjects, where P with the
higher rhIGF-1 dose was 10% and 4% different, respectively, from
P with the lower dose. The estimated P was not different between
the three groups at either dose of rhIGF-1, although the mean P
value for each group varied from 34 to 61 pg/kg/day.
Discussion
was significantly shorter in the MHD and CAPD patients as
compared to normals after the 100 pg/kg dose (P < 0.025; Table
2). There was no difference in the AUC or serum clearance of
IGF-1 with either dose among the three groups. After the 50
pg/kg rhIGF-1 dose, the volume of distribution (Vd) of IGF-1 was
not different in the three groups (Table 2, Fig. 3). In the MHD
and the CAPD patients, the Vd was essentially unchanged after
the 100 tg/kg dose as compared to the 50 pg/kg dose. In the
normals, the Vd also did not rise significantly with the 100 pg/kg
dose. However, the absolute values for Vd tended to rise more in
the normal individuals, and the Vd with the 100 pg/kg dose was
We studied the pharmacokinetics of rhIGF-1 because of the
growing interest in both the use of growth hormone and IGF-1 for
the treatment of patients with renal failure as well as other clinical
disorders [4, 16—20]. Growth hormone stimulates the synthesis
and release of IGF-1 which mediates most, if not all, of the
anabolic effects of growth hormone [1]. Growth hormone has
been used successfully for the treatment of impaired growth in
children with chronic renal failure [21—231, and both growth
hormone and rhIGF-1 have been used experimentally to treat
malnutrition. Currently, there are no published data on the
pharmacokinetics of rhIGF-1 in patients with chronic renal fail-
ure. Since, in renal failure, serum concentrations of some IGF-1
Table 3. Estimated endogenous production of IGF-10.25
0.20
,
.2 0.15
C,)
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_____________________
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*
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50 100
Dose of rhlGF-1, pg/kg body wt
Fig. 3. The volume of distribution of IGF-1 calculated after the injection of
two separate doses of rhIGF-1, 50 pg/kg and 100 pg/kg body weight, in
maintenance hemodialysis patients (A), CAPD patients (0), and normal
individuals (S). Brackets indicate SCM. N = 6 for each group. * Significantly
different from normal adults, P < 0.005.
The value listed for each group is the mean value (±sEM) of the average
production rates calculated from each dose of rhIGF-1. See Methods for
discussion of assumptions made with these calculations.
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binding proteins are abnormal [24—27] and the contribution of the
kidneys to the synthesis, degradation and urinary excretion of
IGF-1 should be reduced, it would not be unexpected for the
metabolic fate of IGF-1 to be altered.
In all three groups when the dose of rhIGF-1 was doubled,
there was a significant increase in the maximum serum IGF-1
concentration and the maximum increment in serum IGF-1 above
baseline (m; Table 2). The AUC tended to increase with the
higher dose, although this rise was significant only in the CAPD
patients. When the rhIGF-1 dose was doubled in the normal
subjects, the rise in Cmax and maxwas disproportionately small.
Cma,, rose by only 28% and by 42%. These findings are
similar to the results following injection of 50 and 100 j.Lg/kg or 40
and 80 gfkg of rhIGF-1 in healthy adults by Wilton and
associates, Hizuka and coworkers, and Stong and Raskin [14, 15,
28]. These investigators also noted a disproportionally smaller rise
in Cm and zm with the higher rhIGF-1 dose. In contrast, in the
MHD and CAPD patients, in the present study when the dose of
rhIGF-1 was doubled, the Cm and maxalso increased by about
100%. Indeed, the Cm and with the 100 pg/kg dose of
rhIGF-1 were significantly greater in both the MHD and CAPD
patients as compared to the normal subjects.
Perhaps the most striking observation from this study was that
the MHD and CAPD patients, as compared to the normal adults,
tended to have a shorter half-life and a reduced Vd. These
differences were statistically significant with the higher dose of
rhIGF-1 (100 tg/kg; Table 2, Fig. 3). The cause for the smaller Vd
in the dialysis patients could be due to elevated serum IGF-1
binding proteins (IGFBP) and binding protein fragments. Several
studies have described either increased serum concentrations of
IGFBP and binding proteins fragments [7, 25, 26] or an increased
serum binding capacity for IGF-1 [7, 8, 29] in patients with chronic
renal failure. Serum IGFBP-1, IGFBP-2, IGFBP-4 and IGFBP-6
are increased two- or threefold in adults with advanced renal
failure [27, 30]. Serum IGFBP-3, the most abundant serum
IGFBP, is variously reported to be normal or increased in chronic
renal failure [24, 31], whereas serum concentrations of the large
ternary IGFBP-3 complex which normally is responsible for most
of the serum binding of IGF-1 [32] appears to be reduced in
chronic renal failure [24]. These observations provide indirect
evidence in support of the thesis that increased serum IGF-1
binding is a cause for the reduced Vd in dialysis patients.
The mechanism for the reduced serum IGF-1 half-life in the
dialysis patients is also uncertain. Some plasma IGF-1 binding
proteins have shorter half-lives [32]. If these binding proteins are
increased in renal failure patients, it might lead to a shorter IGF-1
half-life.
In spite of the almost total absence of renal function in the
dialysis patients, it was somewhat surprising that their serum
IGF-1 half-life was not increased. The kidney is a major site for
the degradation of peptides, including peptide hormones [33].
Hence, it would not be unexpected for the kidneys to be a major
site for the catabolism of rhIGF-1. There are currently no data on
the metabolism of IGF-1 by the kidney. The normal urinary IGF-1
excretion appears to be quite low relative to the total amount
injected in the present study or estimated to be synthesized
endogenously (see below) and is roughly only about 0.1 to 2.0
pg/day in adult men and women [5, 34]. Hizuka et al reported that
in normal men, urinary IGF-1 excretion increased from a baseline
level of 0.1 igIday to 1.4 pg/day after the subcutaneous injection
of 100 g rhIGF-lIkg body wt [5]. The present results indicate
that the loss of the metabolic activity of the kidney do not
substantially increase the half-life or decrease the SC1 of IGF-1 in
renal failure patients. These findings suggest that the normal
kidneys do not play a major role in the total body catabolism or
clearance of IGF-1. It should be noted that the foregoing consid-
erations assume that the bioavailability of subcutaneously injected
rhIGF-1 is 100%, a finding that Kabi Pharmacia is reported to
have found [14].
Wilton and coworkers have published the only other pharma-
cokinetic analysis of IGF-1 in normal humans [14]. These authors
gave subjects a subcutaneous injection in the thigh of 40 and 80 p.g
rhIGF-1/kg body wt. Although the SC1 for IGF-1 was similar to
the present results, the C, was lower and the Tm, half-life, and
Vd were greater than in the normals in the present study.
Subcutaneous injection of insulin is associated with variable
absorption kinetics, depending on the location of injection [35].
There is a greater lag time and higher Tm for 1251-insulin when
it is injected subcutaneously in the thigh as compared to the
abdomen [35]. If a similar phenomenon exists for IGF-1, this
could explain the discrepant findings between the present study
and that of Wilton et al [14].
Our estimate of the assumed endogenous production of IGF-1
is about 49 g!kg/day (3.1 mg/day) in normal adults and roughly
similar in the MHD (61 g/kgIday) and CAPD (34.5 tgfkg/day)
patients (Table 3). Our data for normal adults are similar to that
reported by Wilton et al, 38 jLg/kg/day (3 mg/day) [14]. These data
indicate that the two rhIGF-1 doses employed in the present
study, 50 and 100 JLg/kg body wt, are roughly similar to our daily
assumed endogenous production of IGF-1 in the normal and
dialysis subjects.
The results of the present study indicate that, although the
pharmacokinetics of rhIGF-1 following a single subcutaneous
injection are different in MHD and CAPD patients as compared
to normal adults, these differences are not marked, particularly at
lower (that is, 50 j.Lgfkg body wt) doses of rhIGF-1. With the 100
pg/kg dose, serum IGF-1 concentrations are greater in MHD or
CAPD patients than in normal individuals for the first four hours,
but by 10 to 12 hours after injection of rhIGF-1, the serum levels
are similar. Also, for each dose of rhIGF-1, over the 24 hour
period of observation, the AUC and, hence, exposure to the
compound was similar in the normal and dialysis patients. If
higher peak serum IGF-1 levels are hazardous, it may be prefer-
able to give chronic renal failure patients smaller, more frequent
injections of rhIGF-1 to prevent abnormally high serum IGF-1
concentrations. On the other hand, the shorter IGF-1 half-life in
renal failure suggests that IGF-1 is not more likely to accumulate
with extended treatment.
It is not known whether the pharmacokinetics of IGF-1 will
change in the dialysis subjects with multiple doses. RhIGF-1
injections are known to increase serum concentrations of some
IGF-1 binding proteins—particularly IGF binding protein 2 [36].
A rise in serum binding proteins could alter IGF-1 pharmacoki-
netics. However, in three studies of normal adults given daily
subcutaneous injections of rhIGF-1 for seven days, most pharma-
cokinetic parameters did not change dramatically [5, 14, 28]. It is
possible that the rate of endogenous IGF-1 synthesis or catabo-
lism or the rise in serum IGF-1 binding proteins in response to
repeated administration of rhIGF-1 may be different in MHD or
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CAPD patients than in normal adults. Further studies will be
necessary to answer this question.
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